Prospective Research Assessments in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Purpose

To examine how multiple myeloma is treated by doctors all over the world, how people respond to these treatments, & the economic impact of these treatments

Criteria

People ≥ 18 years old                        

Have started treatment for multiple myeloma within 90 days before consent for this study or plans to begin treatment within 30 days after consent.

Must fit into 1 of the following groups:

Group A: People whose multiple myeloma has returned after at least 1 prior line of treatment, who will begin a new line of treatment

Group B: People newly diagnosed with multiple myeloma, beginning initial line of treatment

You Cannot: Currently be receiving treatment for another cancer other than multiple myeloma

Currently be participating in another research study for multiple myeloma

Details

The total duration for this study is up to 5 years

Each person who joins this study will have their information collected for the study:

· Every 3 months for the 1st year

· Every 6 months for years 2-5



Interested in more information on this clinical research study?

Contact WK Cancer Center Clinical Research Department at 318-212-8671

Interested in more information? Contact Us:

Hematology Oncology Associates

IRB: Quorum
IRB Number:
Trial Type: NA
Sponsor: Bistrol Myers Squibb